Call for vigilance – red flags in systemic lupus erythematous
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Abstract
Systemic Lupus Erythematous (SLE) is a multisystem autoimmune disease. It has been
identified as the underlying cause for death in an average 1,034 deaths from 2000 and 2014. Our
cases highlight two rare but life-threatening complications of SLE; catastrophic antiphospholipid
syndrome (CAPS) and diffuse alveolar hemorrhage (DAH) with mortality as high as 50-90%.
Both cases presented with respiratory symptoms, required meticulous monitoring in ICU and
were initially treated with broad spectrum antibiotics. However, unlike pneumonia, these patients
required immunosuppressive and plasmapheresis leading to clinical improvement.
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Introduction
Systemic lupus erythematous (SLE) is an autoimmune disease affecting multiple organs. The
prevalence of systemic lupus erythematous is reported between 20-150 cases per 100,000.1
According to one estimate there is a prevalence of 161,000 with definite SLE and 322,000 with
probable SLE in the general population.2 It was identified as the underlying cause of death for
an average 1,034 deaths between 2000 and 2014.3 SLE can prove fatal due to disease activity or
concurrent infections. We present two rare but life-threatening complications of SLE:
catastrophic antiphospholipid syndrome (CAPS) and diffuse alveolar hemorrhage (DAH), both
of which can have a mortality as high as 50-90%.4,5
First Case Description
A 39-year-old African-American female presented with soreness of bilateral lower extremities,
more pronounced proximally, with difficulty in ambulation for the past four weeks. Vitals on
admission were significant for low grade fever (100.5 F) and oxygen saturation 99% on 2 L
oxygen. Physical exam was significant for macular rash on bilateral lower extremities and
decreased breath sounds in bilateral lung bases.
Pertinent labs at the time of admission:
LAB VALUES
WBC: 20.0/mm3
Hemoglobin: 9.6 (at baseline)
Platelets: 484
Creatinine Kinase: 1121
CRP: 23.9
ESR: 71

REFERENCE RANGES
4.30-10.80/mm3
12-16 g/dl
150-400 10^3/cmm
14- 54 U/L
0-1 mg/dl
1 -20 mm/hr

Chest Imaging showed left postero-basal infiltrate and developing right infiltrate (Figure 1) and
pericardial effusion (Figure 2)

Figure 1: CT chest with and without contrast: Diffuse reticular nodular infiltrates
and scattered patchy ground glass infiltrates.

Figure 2: Computerized tomography (CT) chest with and without contrast which
shows mild cardiomegaly with pericardial effusion (dotted arrow).

On the second day of hospitalization the patient was transferred to the intensive care unit (ICU)
because of increased shortness of breath with continuous fever and subsequently required
intubation for hypoxia. Shortly after that she developed hypotension requiring brief pressor
support. The patient started to develop discoloration of her distal digits which was initially
thought to be a result of hypo perfusion during the hypotensive crisis. The working diagnosis at
this point was pneumonia causing sepsis and thus antibiotic coverage was broadened. During the
ICU stay, the patient also developed acute renal failure with decreased urine output requiring
intermittent hemodialysis. Echo demonstrated pericardial effusion with tamponade, which was
subsequently drained and 600 ml of serous fluid was removed. Pericardial fluid was positive for
antinuclear antibodies (ANA). Her blood work up also came back positive for ANA (titer levels
of 1:600) with other notable findings being low complement levels and positive antiphospholipid
antibody and SSA Ab.
At this point patient’s infectious work up including sputum, blood culture and bronchoalveolar
lavage which remained negative and patient’s respiratory failure was attributed to acute lupus
pneumonitis. She underwent renal biopsy which demonstrated lupus nephritis, WHO class IIB
and III.
Antibiotics were discontinued and per rheumatology she was started on 1g/day of methyl
prednisone, IV Cytoxan and heparin drip. After a prolonged hospital stay she was weaned off
from the ventilator and was maintained on prednisone for suppression of her SLE and
anticoagulation in context of digit hypo perfusion. Two months later she was readmitted and
underwent right thumb, index, middle, small finger and left second and fifth toe amputation.
Microscopic examination of upper extremity amputation revealed thrombi in the medium-size
arteries.
In light of histological manifestation of vessel occlusion, presence of antiphospholipid antibody,
and rapid progression of symptoms with multiple digit involvement led to a diagnosis of
catastrophic antiphospholipid syndrome.4 The patient subsequently was maintained on lifelong
anticoagulation and immunosuppression.
Second Case Description
A 26-year-old African-American female with a past medical history significant for asthma,
seasonal allergies and recent diagnosis of SLE (mainly mucocutaneous and inflammatory
arthritis) presented with a two-week history of progressive dyspnea, hemoptysis and nocturnal
fevers.
The patient reported that initially she had dyspnea at rest with occasional blood-tinged sputum
but now developed hemoptysis with accompanying fevers at night time. She denied any sick
contacts but worked at a daycare center. On presentation, she was tachypneic, requiring 3 L of
oxygen. She was afebrile and normotensive. Physical exam was significant for anterior cervical
and submandibular lymphadenopathy. Chest auscultation was remarkable for bilateral rhonchi,
left lower lobe wheezing with skin findings positive for malar and discoid rash noted on the face
and ear respectively.

Pertinent Labs at the time of admission:
LAB VALUES
REFERENCE RANGES
Hemoglobin: 5.4

12-16 g/dl

(Baseline-11-12)
ANA: 1:10,240

<1:40

ESR: >121

1 -20 mm/hr

Complement C4: <2

10-40 mg/dl

Complement C3: 66

90-180 mg/dl

Computerized tomography angiography (CTA) of chest was significant for diffuse adenopathy
and ground glass opacities as seen in Figure 3.
.

Figure 3: CT Angiography of chest: Confluent diffuse bilateral ground glass opacities/confluent
airspace consolidations with a subtle dependent gradient of airspace opacity.
The patient was admitted to the ICU and started on broad-spectrum antibiotics. She underwent
bronchoalveolar lavage which was consistent with diffuse alveolar hemorrhage (DAH).
Rheumatology was consulted and the patient was promptly started on a five-day course of 1
g/day methyl prednisone (along with PCP prophylaxis and IV immunoglobulin). Four days later

she had worsening cough and her respiratory function declined, requiring intubation. Femoral
dialysis catheter was placed and plasmapheresis initiated for 5 days along with rituximab and
cyclophosphamide. During her course of admission mycoplasma IgM antibody (1312 U/ml) and
fungi tell came back positive. Infectious diseases was consulted and antimicrobial coverage was
augmented with voriconazole. On the ninth day of admission she was extubated, antibiotics and
antifungal were discontinued as infectious and blood workup (except mycoplasma) remained
negative. Mycoplasma pneumonia treatment was completed with 7-day course of antibiotic
coverage (which patient was on since admission). Subsequently she was transferred to the floor
with continued improvement in her oxygen requirements. She was maintained on PCP
prophylaxis with her prednisone taper and ultimately discharged on her home regimen of
hydroxychloroquine with outpatient follow-up.
Discussion
These cases highlight that not every patient who presents with respiratory failure and lung
infiltrates (as seen in figures 2 and 3) may have pneumonia requiring broad-spectrum antibiotics.
Moreover, these lethal complications can be the first manifestation of SLE itself as illustrated in
the case of catastrophic antiphospholipid syndrome (case one). Both cases required close
monitoring in an intensive care setting and treatment with immunosuppressive agents:
corticosteroids and cyclophosphamide. Additionally, the patient in case two also required plasma
exchange.4 Anticoagulants are required in CAPS whereas extracorporeal membrane oxygenation
(ECMO) can be used in severe cases of DAH.6 A high index of suspicion, early recognition of
symptoms and treatment with immunosuppressive agents remain the keys to improve quality of
care, prevent progression of organ failure and hence prevent mortality in CAPS and DAH.
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